Label date: 20250827 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: A DPP-4 inhibitor believed to act by slowing incretin inactivation. It increases and prolongs active GLP-1 and GIP levels, which influence insulin and glucagon in a glucose-dependent manner.
On both cards: Common side effects — Nasopharyngitis · Warnings — Pancreatitis
Only on the Sitagliptin card: Used for — Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes · Common side effects — Upper respiratory tract infection; Headache · Warnings — Heart failure; Acute renal failure · Interactions — Insulin or insulin secretagogues (sulfonylureas)
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.